WO2007094200A1 - 美白用の化粧料 - Google Patents
美白用の化粧料 Download PDFInfo
- Publication number
- WO2007094200A1 WO2007094200A1 PCT/JP2007/051999 JP2007051999W WO2007094200A1 WO 2007094200 A1 WO2007094200 A1 WO 2007094200A1 JP 2007051999 W JP2007051999 W JP 2007051999W WO 2007094200 A1 WO2007094200 A1 WO 2007094200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- mass
- compound
- acid
- whitening
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Definitions
- the present invention relates to a cosmetic for whitening.
- cosmetics include those corresponding to products classified as quasi-drugs in Japan.
- the whitening agent sometimes has problems in surface properties such as stability and safety.
- ascorbic acid can be easily oxidized and unstable in systems containing a lot of water such as water-containing cosmetics, and can cause discoloration of a topical skin preparation (whitening agent).
- hydrogen peroxide has problems in terms of storage stability and safety, and gnorethione and colloidal sulfur give off a significant off-flavor, so their use as a whitening agent component is restricted.
- hydroquinone, catechol, etc. may have safety problems such as skin irritation and allergic properties. In such a technical background, it is desired to develop a new whitening material that works effectively and satisfies stability and safety.
- thiophene derivatives represented by the following general formula (I) have an antioxidant action, an anti-inflammatory action based on the suppression of prostaglandins, an anti-allergic action and an anti-rheumatic action.
- Patent Document 1 Patent Document 2, Patent Document 3, Patent Document 4, Non-Patent Document 2, and Non-Patent Document 3.
- Patent Document 1 JP-A-53-141265
- Patent Document 2 Japanese Patent Laid-Open No. 63-008380
- Patent Document 3 JP-A 63-502281
- Patent Document 4 Japanese Patent Publication No. 06-501919
- Non-patent document 1 Supervised by Katsuyuki Takeda et al., “Evaluation technology and future prospects of cosmetics”, published by Yakuji Nippo (2001)
- Non-Patent Document 2 Agents and Action, Vol.12, No.5, p.674-683, (1982)
- Non-Patent Document 3 B ioorganic & Medicinal Chemistry, Vol .. 11, p4207-4216, (2003) Disclosure of the Invention
- the present invention has been made in view of the above-described situation, and provides a cosmetic or the like that exhibits an excellent effect on the improvement of 'skin' prevention of skin pigmentation such as buckwheat '. It is an issue.
- the present inventors have determined that a specific thiophene derivative (specifically, a compound represented by the general formula (I) and / or a salt thereof) has been found to have a strong inhibitory effect on pigment cell melanin production. Furthermore, the inventors have found that when the above thiophene derivative is blended in a base material such as a cosmetic, it exhibits an excellent effect of preventing and improving pigmentation on the skin, thereby completing the present invention. That is, the present invention is as follows.
- R 1 and R 2 each independently represents a secondary or tertiary alkyl group having 3 to 7 carbon atoms, and R 3 represents a hydrogen atom or 1 to 4 carbon atoms. Or an alkyl group having 1 to 4 carbon atoms.
- R 1 and R 2 each independently represents a secondary or tertiary alkyl group having 3 to 7 carbon atoms.
- the compound represented by the general formula (II) is 2,6-di-tert-petite 4-one (2′-tenol) phenol (compound (1)), (2) Cosmetics for whitening as described in).
- the cosmetic for whitening according to any one of (1) to (5) characterized in that it contains at least one kind of polyhydric alcohol.
- the present invention also relates to the use of the compound represented by the general formula (I) and Z or a salt thereof for the production of a whitening cosmetic, and the general formula (I).
- the method is characterized by applying the compound and Z or a salt thereof to the skin to be whitened.
- FIG. 1 Western blotting showing the expression of tyrosinase and Trp-1, Trp_2 proteins (drawing substitute photo).
- R 1 and R 2 each independently represents a secondary or tertiary alkyl group having 3 to 7 carbon atoms, that is, a bulky substituent.
- R 1 and R 2 are isopropyl group, isobutyl group, sec-butyl group, tert-butyl group, isoamyl group, sec-amyl group, and tert-amyl group. Of these, the tert-butyl group is preferred.
- the di-tert-butyl form in which R 1 and R 2 are both tert-butyl groups is more preferred.
- R 3 may be a hydrogen atom or an arbitrary substituent selected from an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms.
- the substitution position is arbitrary, preferably an alkyl group having 1 to 4 carbon atoms, or an alkoxy group having 1 to 4 carbon atoms.
- R 3 is particularly preferably a hydrogen atom. That is, in the present invention, the compound represented by the general formula (I) is preferably a compound represented by the general formula (II).
- the compound that is an essential component of the cosmetic of the present invention is more preferably 2,6-di-te.
- rt_Butyl_4_ (2′-tenol) phenol that is, the compound represented by the compound (1).
- the compound represented by the general formula (I) is free and can be used in the cosmetic of the present invention. It can also be used as a salt using alkali or the like.
- alkali metal salts such as sodium salt and strength salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- organic amine salts such as ammonium salt, triethanolamine salt and triethylamine salt
- lysine salt and arginine salt Preferred examples include basic amino acid salts of
- these compounds can be produced by any method, for example, the force that can be produced by the method outlined in the following scheme 1 or 2, is not limited to these methods.
- the target compound can be produced by appropriately changing the following methods.
- 3,5_dialkyl_4-hydroxybenzoic acid is treated with thionyl chloride in a conventional manner to give 3,5_dialkyl_4-hydroxybenzoic acid acid chloride.
- This acid chloride ( ⁇ ) is treated with a Lewis acid such as chloroanoleminium or titanium tetrachloride in a suitable solvent such as carbon disulfide.
- a Lewis acid such as chloroanoleminium or titanium tetrachloride
- a suitable solvent such as carbon disulfide.
- the compound of the general formula (I) can be obtained by adding thiophene ( ⁇ ) and allowing Friedel-Craft reaction.
- 3,5_di-alkyl_4-hydroxybenzoic acid for example, 3,5_di-tert-butyl_4-hydroxybenzoic acid commercially available from Sigma-Aldrich Can be used.
- the compound (B) an unsubstituted form in which R 3 is a hydrogen atom, a substituted form such as methylthiophene or methoxythiophene can be used.
- Thiophenecarboxylic acid is treated with thionyl chloride in a conventional manner to obtain an acid chloride (C) of thiophencarboxylic acid.
- This acid chloride (C) is treated with a Lewis acid such as salt-aluminum or tetrasalt-aluminum titanium in a suitable solvent such as carbon disulfide.
- a Lewis acid such as salt-aluminum or tetrasalt-aluminum titanium in a suitable solvent such as carbon disulfide.
- the compound of general formula (I) can be obtained by adding 2,6-dialkylphenol (D) and carrying out Friedel-Craft reaction.
- R 3 is a hydrogen atom 2_thiophenecarboxylic acid, 3_methyl_2-thiophenecarboxylic acid, 5methyl_2 -Thiophenecarboxylic acid and the like can be used.
- the acid chloride of 2-thiophenecarboxylic acid is used as the compound (C)
- a compound represented by the general formula (II) is obtained.
- 2,6 dialkylphenol (D) 2,6 ditert-butylphenol, 2,6 diisopropylphenol, and the like commercially available from Sigma-Aldrich can be used.
- the compound represented by the general formula (I) is excellent in melanin production inhibitory action.
- many compounds having an inhibitory action on melanin production are based on a mechanism that directly inhibits tyrosinase or decomposes tyrosinase.
- the compound represented by the general formula (I) inhibits melanin production by a mechanism different from that caused by tyrosinase degrading action or tyrosinase direct inhibiting action.
- the cosmetic of the present invention contains the compound represented by the above general formula (I) and / or a salt thereof as an essential component.
- the cosmetic of the present invention may contain only one type of compound represented by the general formula (I) or a salt thereof, or may contain a plurality of types in combination.
- the preferred content of the compound represented by the general formula (I) in the cosmetic of the present invention may vary depending on the purpose of use of the cosmetic, the state of the skin, the dosage form, and the site to be applied. It is at least mass%, preferably at least 0.001 mass%, more preferably at least 0.01 mass%. On the other hand, the upper limit is 3% by mass or less, preferably 1% by mass or less, and more preferably 0.8% by mass or less.
- the compound represented by the general formula (I) of the present invention has a strong melanin production inhibitory effect, it can also be used for quasi drugs in Japan or similar products in other countries.
- the cosmetic of the present invention is used on a skin condition site where inflammation has not occurred. That is, it is preferable that the cosmetic of the present invention does not aim at anti-inflammatory.
- the cosmetic of the present invention is applied, for example, to prevent pigmentation such as simian buckwheat on the skin, in which melanin production is generally enhanced but no inflammatory reaction occurs. In other words, it is preferably applied to a portion having pigmentation.
- the cosmetic of the present invention has a melanin production-inhibiting action, and has an action to prevent and improve the stain "prevents pigmentation such as buckwheat". It is also a preferred form of the present invention to display an effect such as “suppress melanin production and prevent spots and freckles” and inform the consumer of the form of effective use.
- the cosmetic of the present invention comprises 1,3-butanediol in addition to the compound represented by the general formula (I). , Containing at least one polyhydric alcohol selected from dipropylene glycol, isoprene glycol, 1,2_pentanediol, 2,4_xylene glycol, 1,2-hexanehexane, 1,2_octanediol I also like that. These polyvalent alcohols have an action of enhancing the whitening effect of the cosmetic of the present invention.
- the content of these polyhydric alcohols is not particularly limited, but is preferably 0.:! To 30% by mass, more preferably 1 to 20% by mass, and even more preferably 5 to 10% by mass. . Further, the content of the compound represented by the general formula (I) is preferably 5 to 50 times by mass, more preferably 5 to 20 times by mass.
- surfactant examples include fatty acid soap (sodium laurate, sodium normitate, etc.), anionic surfactants such as potassium lauryl sulfate, alkylsulfuric triethanolamine ether, salt ⁇ stearyl trimethyl ammonium, Cationic surfactants such as benzanololeconium chloride and laurylamine oxide, imidazoline amphoteric surfactants (2-cocoyl-1-2-imidazolinyl hydroxide-1-1-carboxyethyloxy disodium salt, etc.) , Betaine surfactants (alkyl betaines, amide betaines, sulfobetaines, etc.), amphoteric surfactants such as isylmethyltaurine, sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin Fatty acids (glyceryl monosteale ), Propylene glycol fatty acids (glyce
- the content of these surfactants is not particularly limited, but is preferably 0.1 to 10% by mass, and more preferably 0.2 to 5% by mass.
- the content of the compound represented by the general formula (I) is preferably 0.:! To 20 times by mass, and more preferably 0.2 to 20 times by mass.
- the cosmetic of the present invention contains an ultraviolet protective agent.
- an ultraviolet protective agent contained in the cosmetics and quasi drugs of the present invention it is sufficient if exposure to ultraviolet rays, which is a deteriorating factor such as a stain, can be reduced.
- an ultraviolet protective agent various powders having an ultraviolet scattering effect and compounds having an ultraviolet absorbing effect are used.
- the surface may be treated, My strength, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, anhydrous caustic acid (silica), aluminum oxide,
- organic powders include polyethylene powder, methyl polymethacrylate, nylon powder, organopolysiloxane elastomer, and the like.
- a compound having such an ultraviolet absorption effect a compound having an aromatic ring is generally sufficient.
- vitamin B vitamin B, vitamin B, vitamin B, vitamin B, vitamin B, and
- Aromatic rings such as vitamin B group such as Tamine B, vitamin E, ubiquinone, folic acid
- cycloaliphatic vitamins For example, cycloaliphatic vitamins.
- the cosmetic composition of the present invention includes, in addition to the above-mentioned components, various components generally used for pharmaceuticals, cosmetics, and the like, that is, fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, estenoles, oil agents, Contains aqueous ingredients, powder ingredients, moisturizers, thickeners, colorants, fragrances, antioxidants, pH adjusters, chelating agents, preservatives, UV protection agents, vitamins, other whitening agents, anti-inflammatory agents, etc. sell.
- various components generally used for pharmaceuticals, cosmetics, and the like that is, fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, estenoles, oil agents, Contains aqueous ingredients, powder ingredients, moisturizers, thickeners, colorants, fragrances, antioxidants, pH adjusters, chelating agents, preservatives, UV protection agents, vitamins, other whitening agents, anti-inflammatory agents, etc. sell.
- fats and waxes include macadamia nut oil, apogado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, Oils such as palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, molasses, hydrogenated castor oil, beeswax, candelillaro, carnauba wax, botalow, lanolin, reduced lanolin, hard lanolin, jojoba wax, waxes, liquid paraffin, squalane, pristane, Hydrocarbons such as ozokerite, paraffin, ceresin, petrolatum, microcrystalline wax, etc., and fatty acids include oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid, etc.
- higher fatty acids examples include cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, otatildodecanol, myristyl alcohol, cetostearyl alcohol, and esters include cetyl isooctanoate, myristine.
- Cyclic polysiloxane, amino-modified polysiloxane, polyether examples thereof include silicone oils such as modified polysiloxanes such as tellurium-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane.
- Examples of the moisturizing agent include polyhydric alcohols such as polyethylene glycol, glycerin, diglycerin, erythritol, sonolebitol, xylitolol, maltitol, propylene glycol, sodium pyrrolidone carboxylate, lactic acid, sodium lactate and the like.
- polyhydric alcohols such as polyethylene glycol, glycerin, diglycerin, erythritol, sonolebitol, xylitolol, maltitol, propylene glycol, sodium pyrrolidone carboxylate, lactic acid, sodium lactate and the like.
- Examples of the inorganic pigment may include bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine blue, bitumen, titanium oxide, zinc oxide and the like whose surface may be treated.
- the surface may be treated, such as titanium mica, fish phosphorus foil, oxysalt bismuth, etc., and the organic pigments may be raked red 202, red 228, red 226, Yellow 4, Blue 404, Yellow 5, Red 505, Red 230, Red 223, Orange 201, Red 213, Yellow 204, Yellow 203, Blue 1, Green 201, Purple 201, red 204, etc.
- Examples of the whitening component or whitening agent other than the compound represented by the general formula (I) include pantethein mono-S-sulfonic acid, isoferulic acid, ascorbic acid monodalcoside, ascorbic acid phosphate ester salt, 4_n —4_ (C4-10) alkylresorcinols such as butylresorcinol, arbutin, kojic acid, linolenolic acid, linolenolic acid methinore, tranexamic acid, tranexamic acid methylamide, and the like.
- the cosmetic of the present invention includes lower alcohols (ethanol, isopropanol, etc.), or vitamin A or a derivative thereof, vitamin Ds, pantothenes in addition to the above-mentioned vitamins. Acids, pantethine, coenzyme Q10, etc. may be included.
- the cosmetic dosage form of the present invention is arbitrary, and can be used without limitation as long as it is usually used for this type of cosmetic or quasi-drug.
- the compound represented by general formula (I) penetrates into the skin and exhibits whitening action and melanin production inhibiting action. Desirable forms such as lotions, emulsions, ointments, creams, lotions are desirable.
- the pack fee is also a preferable form since an effect due to blocking is expected.
- the cosmetic of the present invention can be produced in the same manner as in the production of ordinary cosmetics except that it contains the compound represented by the general formula (I).
- An oil-in-water cream was prepared according to the formulation shown below. That is, the components (A) were mixed and heated to 80 ° C. On the other hand, each component of (B) was mixed and heated to 80 ° C. To the mixture of (A), the mixture of (B) was added and stirred to emulsify, and then cooled to 35 ° C. to obtain the term 1.
- Glycerol monostearate 10.0 mass 0/0 Liquid paraffin 10.0 mass%
- BHT Dibutylhydroxytoluene 0.01 mass%
- a pack was prepared according to the formulation shown below. Each component of (A) was dispersed and dissolved at room temperature, and the mixture of (B) was added and dissolved uniformly to obtain a pack.
- cream 1 containing 1,3_butanediol and 1,2 ⁇ ntandiol It can be seen that the ⁇ L value is smaller at the site where cream 3 is applied, compared to the site where cream 5 is replaced with water, and the recovery of brightness is accelerated.
- cream 4 in which 1,3-butanediol was replaced with glycerin had a slightly lower brightness recovery promoting effect than cream 1 and cream 2. That is, creams 1 and 3 containing divalent polyhydric alcohols such as 1,3-butanediol and 1,2_pentanediol are considered to be excellent in preventing and improving pigmentation. .
- L- / 3-(3,4-dihydroxy Phenyl) alanine (L—DOPA) was dissolved in 10 mM sodium phosphate buffer (pH 6.8) to a concentration of 0.1 (w / v)%.
- ⁇ ⁇ 5 ag / 80 a L of crude tyrosinase protein solution f Night was added at 80 z L each, and DMSO was added to 10 ⁇ , 100 ⁇ , and 1000 ⁇ . 20 ⁇ L of the compound (1) solution was added to each of 3 wells.
- phenylthiourea known as a tyrosinase activity inhibitor
- DMSO was added to each of the 3 wells at 20 zL.
- a 0.1% dopa solution was added to each tool solution in 100 zL at a time, and the absorbance at 450 nm was immediately measured with a plate reader, and this was taken as the 0 minute value.
- 96 well plate After incubating for 10 minutes at 37 ° C in a plate reader, the absorbance at 450 nm was measured again, and this was taken as the value for 10 minutes.
- the value obtained by subtracting the 0-minute value from the 10-minute value for each well was defined as the 0 to 10-minute absorbance change value, and the control 0 to 10-minute absorbance change value average was 100%. Dopa oxidation activity was measured. The results are shown in Table 5.
- Such mechanisms include inhibition of the expression of tyrosinase and tyrosinase-related proteins such as Trp-1, Tp-2, indirect inhibition of tyrosinase activity by intracellular metabolites, etc. Inhibition of the transport of can be considered.
- the filter was washed with TPBS, and then reacted with secondary antibody-containing TPBS for 1 hour (room temperature).
- the antibodies used and the dilution ratios are as follows.
- Anti-goat IgG Horseradish peroxidase-conjugated antibody (Rono, (Santa Knorez, SC-2033), 1/7, 500 dilution
- each protein was detected using an ECL Plus western blotting detection system.
- ECL Plus western blotting detection system a cooled CCD camera-mounted chemical issue detector (manufactured by ATT Ltd.) was used. The results are shown in Figure 1.
- the compound (1) is at or above the concentration at which the melanin production inhibitory effect was confirmed in ⁇ Test Example 1>.
- a whitening cosmetic that exhibits an excellent effect on prevention and improvement of skin pigmentation such as white buckwheat.
- the cosmetic of the present invention can be used safely.
- the present invention can be applied to whitening cosmetics or quasi-drugs for whitening.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008500450A JP5140575B2 (ja) | 2006-02-14 | 2007-02-06 | 美白用の化粧料 |
CA002641106A CA2641106A1 (en) | 2006-02-14 | 2007-02-06 | Skin-whitening cosmetic |
AU2007216009A AU2007216009A1 (en) | 2006-02-14 | 2007-02-06 | Skin-whitening cosmetic |
EP07713841A EP1987811A1 (en) | 2006-02-14 | 2007-02-06 | Skin-whitening cosmetic |
BRPI0707660-6A BRPI0707660A2 (pt) | 2006-02-14 | 2007-02-06 | cosmÉtico para clareamento da pele |
US12/162,977 US20090054515A1 (en) | 2006-02-14 | 2007-02-06 | Skin-whitening cosmetic |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-036842 | 2006-02-14 | ||
JP2006036842 | 2006-02-14 | ||
JP2006-296552 | 2006-10-31 | ||
JP2006296552 | 2006-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007094200A1 true WO2007094200A1 (ja) | 2007-08-23 |
Family
ID=38371386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/051999 WO2007094200A1 (ja) | 2006-02-14 | 2007-02-06 | 美白用の化粧料 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090054515A1 (ja) |
EP (1) | EP1987811A1 (ja) |
JP (1) | JP5140575B2 (ja) |
KR (1) | KR20080112229A (ja) |
AU (1) | AU2007216009A1 (ja) |
BR (1) | BRPI0707660A2 (ja) |
CA (1) | CA2641106A1 (ja) |
RU (1) | RU2008136849A (ja) |
TW (1) | TW200800284A (ja) |
WO (1) | WO2007094200A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008139754A1 (ja) * | 2007-05-10 | 2008-11-20 | Pola Chemical Industries Inc. | 2,6-ジ-tert-ブチルフェノ-ル誘導体及び2,6-ジ-tert-ブチルフェノ-ル誘導体を有効成分とするメラニン生成抑制剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9676696B2 (en) * | 2009-01-29 | 2017-06-13 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin and/or hair care actives |
US8084504B2 (en) | 2009-10-02 | 2011-12-27 | Johnson & Johnson Consumer Companies, Inc. | High-clarity aqueous concentrates of 4-hexylresorcinol |
US8906432B2 (en) | 2009-10-02 | 2014-12-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
US20110081430A1 (en) | 2009-10-02 | 2011-04-07 | Simarna Kaur | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER |
BR112012007512A2 (pt) | 2009-10-02 | 2016-11-22 | Johnson & Johnson Consumer | composições compreendendo uma mistura anti-inflamatória |
US20140086859A1 (en) | 2012-09-24 | 2014-03-27 | Johnson & Johnson Consumer Companies, Inc. | Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004345A1 (en) * | 1986-01-17 | 1987-07-30 | Riker Laboratories, Inc. | Topical antiinflammatory compositions |
WO1998043630A1 (en) * | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
WO2001021166A1 (en) * | 1999-09-21 | 2001-03-29 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
US6444221B1 (en) * | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172082A (en) * | 1977-05-16 | 1979-10-23 | Riker Laboratories, Inc. | Substituted thiophenes |
US4677113A (en) * | 1986-04-22 | 1987-06-30 | Riker Laboratories, Inc. | Di-t-butylphenols substituted by a thenoyl group |
-
2007
- 2007-02-06 EP EP07713841A patent/EP1987811A1/en not_active Withdrawn
- 2007-02-06 RU RU2008136849/15A patent/RU2008136849A/ru not_active Application Discontinuation
- 2007-02-06 BR BRPI0707660-6A patent/BRPI0707660A2/pt not_active Application Discontinuation
- 2007-02-06 KR KR1020087022343A patent/KR20080112229A/ko not_active Application Discontinuation
- 2007-02-06 JP JP2008500450A patent/JP5140575B2/ja active Active
- 2007-02-06 US US12/162,977 patent/US20090054515A1/en not_active Abandoned
- 2007-02-06 AU AU2007216009A patent/AU2007216009A1/en not_active Abandoned
- 2007-02-06 WO PCT/JP2007/051999 patent/WO2007094200A1/ja active Application Filing
- 2007-02-06 CA CA002641106A patent/CA2641106A1/en not_active Abandoned
- 2007-02-12 TW TW096104950A patent/TW200800284A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004345A1 (en) * | 1986-01-17 | 1987-07-30 | Riker Laboratories, Inc. | Topical antiinflammatory compositions |
US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
US6444221B1 (en) * | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
WO1998043630A1 (en) * | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
WO2001021166A1 (en) * | 1999-09-21 | 2001-03-29 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008139754A1 (ja) * | 2007-05-10 | 2008-11-20 | Pola Chemical Industries Inc. | 2,6-ジ-tert-ブチルフェノ-ル誘導体及び2,6-ジ-tert-ブチルフェノ-ル誘導体を有効成分とするメラニン生成抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
AU2007216009A2 (en) | 2008-09-18 |
EP1987811A1 (en) | 2008-11-05 |
JP5140575B2 (ja) | 2013-02-06 |
BRPI0707660A2 (pt) | 2011-05-10 |
RU2008136849A (ru) | 2010-03-20 |
JPWO2007094200A1 (ja) | 2009-07-02 |
US20090054515A1 (en) | 2009-02-26 |
KR20080112229A (ko) | 2008-12-24 |
AU2007216009A1 (en) | 2007-08-23 |
CA2641106A1 (en) | 2007-08-23 |
TW200800284A (en) | 2008-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100428915B1 (ko) | 신규한 산화방지제 혼합물 | |
US8247405B2 (en) | Skin lightening compositions with acetylcholinesterase inhibitors | |
WO2007094200A1 (ja) | 美白用の化粧料 | |
JP2020059727A (ja) | キャノーラエキスの使用による皮膚のホワイトニング方法 | |
BR112013012586B1 (pt) | Uso de filtros uv para intensificar a penetração dérmica de resveratrol em composições cosméticas tópicas | |
US8529967B2 (en) | Sunscreen compositions and methods | |
US20210085585A1 (en) | A personal care composition | |
JP2001002558A (ja) | 美白化粧料 | |
CN109661224B (zh) | 用于降低细胞黑色素含量的化合物 | |
JP2003252748A (ja) | 美白用化粧料 | |
US20080233076A1 (en) | Process for stabilizing ascorbic acid compositions | |
JP5198732B2 (ja) | メラニン生成抑制剤 | |
JP6086706B2 (ja) | 高い紫外線吸収効果を有する皮膚外用組成物 | |
JP4842550B2 (ja) | チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白用皮膚外用剤 | |
EP3804690B1 (en) | Skin lightening agent | |
JP2007186441A (ja) | 皮膚外用剤 | |
JP4138679B2 (ja) | 刺激緩和剤 | |
JPH1121226A (ja) | メラニン産生抑制皮膚外用剤 | |
JP2007008818A (ja) | 皮膚外用剤 | |
JP2007008820A (ja) | 皮膚外用剤 | |
US20100158829A1 (en) | Method and Composition for Color Modulation | |
JPH1036247A (ja) | メラニン産生抑制剤及び皮膚外用剤 | |
JP4568527B2 (ja) | ベンゾフラン誘導体及びそれを含有してなる皮膚外用剤 | |
CN101378724A (zh) | 皮肤增白化妆品 | |
JP2020029400A (ja) | 美白剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008500450 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007216009 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007713841 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2641106 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12162977 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780004437.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2007216009 Country of ref document: AU Date of ref document: 20070206 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087022343 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2008136849 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0707660 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080811 |